This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, raise important questions about the extent to which biomarkers can aid in patient care as well as their limitations.
Experts delve into the practical application of monitoring serum NFL levels in clinical practice and how it can inform treatment decisions. The segment explores how a patient's NFL level could serve as an indicator of treatment efficacy. Experts emphasize the importance of observing a decline in NFL levels after initiating therapy, suggesting a positive response to treatment. They agree on the dynamic monitoring potential of NFL, allowing for continuous assessment and response to treatment changes.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.